Literature and guidelines often cite cardiotoxicity rates of 15-20% associated with trastuzumab in patients with HER2-positive breast cancer, primarily on the basis of early trials. A closer look at ...
Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Recent Advances and Strategies This review critically analyzes the incidence of ...
Please provide your email address to receive an email when new articles are posted on . Enalapril was not superior to standard care for preventing chemotherapy-related cardiotoxicity for breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results